# Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/PAVM/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference
Ticker: PAVM
Company: PAVmed
Source: PAVmed
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.pavmed.com
## Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...

## Article Body
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

, / PRNewswire / -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25 th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.

The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website or by clicking here . A replay of the webcast will be archived on the website for 30 days following the live event.

About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .

SOURCE Lucid Diagnostics

For further information: Investor and Media Contact: Matt Riley, PAVmed and Lucid Diagnostics, mjr@pavmed.com
## Recent Company News
- 2026-06-25 13:46 EST — [Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PAVM/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: PAVmed
- 2026-06-25 13:46 EST — [Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/PAVM/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock) — Source: PAVmed
- 2026-06-25 13:46 EST — [Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/PAVM/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock) — Source: PAVmed
- 2026-06-25 13:46 EST — [Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/PAVM/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: PAVmed
- 2026-06-25 13:46 EST — [PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PAVM/pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: PAVmed
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)